Defining and measuring the costs of the HIV epidemic to business firms.
Most published estimates of the costs of the epidemic of human immunodeficiency syndrome (AIDS) have been developed from the societal perspective, attempting to measure the burden of the epidemic to society in this country.
Although societal cost analysis is well-developed, relatively little is known about many of the factors influencing the costs of the epidemic to business firms.
The business community may bear a substantial portion of those costs in the form of health-related benefits provided to workers.
Mots-clés Pascal : SIDA, Virose, Infection, Analyse coût, Economie santé, Impact socioéconomique, Entreprise, Impact social, Etats Unis, Amérique du Nord, Amérique, Homme, Immunopathologie, Immunodéficit
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Cost analysis, Health economy, Socioeconomical impact, Firm, Social impact, United States, North America, America, Human, Immunopathology, Immune deficiency
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0480771
Code Inist : 002B06D01. Création : 199501.